Drugs / Trastuzumab
Trastuzumab
also known as
Herceptin · Herzuma · CT-P6 · Herceptin (trastuzumab) · NSC-688097 · QL1701 · SB3 · trastuzumab-EU · +22 more
Monoclonal antibody targets ERBB2
Regulatory milestones approvals, filings & regulatory actions · 12 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | PHESGO | — | 2024-11-22 | fda.gov ↗ |
| Label expansion | US (FDA) | HERCEPTIN HYLECTA | — | 2024-06-18 | fda.gov ↗ |
| Label expansion | US (FDA) | HERZUMA | — | 2019-05-16 | fda.gov ↗ |
| Label expansions (7) | US (FDA) | HERCEPTIN | — | 2001-12-11 – 2014-03-07 | fda.gov ↗ |
| Approved | EU (EMA) | Herceptin | — | 2000-08-28 | europa.eu ↗ |
| Approved | US (FDA) | HERCEPTIN | — | 1998-09-25 | fda.gov ↗ |
Trials 686 · started per year
today
US approved 1998
EU approved 2000
1
5
18
16
19
14
13
14
29
26
30
19
24
16
41
20
30
34
24
20
22
21
28
29
32
37
33
24
28
15
19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT06098898 | Nov 2023 → Nov 2024 | gastric cancer | Base Therapeutics (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT05238831 | Jan 2023 → May 2026 | female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 0 | NCT04958486 | Jul 2021 → Sep 2023 | posterior fossa ependymoma | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 0 | NCT04102618 | Mar 2019 → Apr 2022 | breast cancer | Oncolytics Biotech | Terminated | No outcome recorded |
| Phase 0 | NCT03321045 | Nov 2017 → Oct 2028 expected | breast cancer | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 0 | NCT02735798 | Apr 2016 → Jun 2017 | metastatic malignant neoplasm in the brain | Pamela Munster | Withdrawn | No outcome recorded |
| Phase 0 | NCT00949247 | Dec 2009 → Jan 2013 | breast cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 169 trials | ||||||
| Phase 1 | NCT07299955 | Feb → Jun 2026 overdue | — | Biocon Biologics UK Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT07216105 | Nov 2025 → Jan 2028 expected | breast cancer, colorectal cancer, endometrial carcinoma, head and neck squamous cell carcinoma +2 | Fate Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05733689 | Jun 2025 → Jun 2027 expected | gastroesophageal adenocarcinoma | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 1 | NCT05553522 | Jan 2024 → Dec 2025 | HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain | Baptist Health South Florida | Terminated | No outcome recorded |
| Phase 1 | NCT06886659 | Jan → Dec 2024 | breast cancer | Incepta Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06162559 | Dec 2023 → Aug 2026 overdue | breast cancer | The Netherlands Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05187182 | Jun 2023 → Jul 2028 expected | esophageal cancer, gastric cancer, gastroesophageal cancer | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05395052 | May 2022 → Aug 2023 | breast cancer, colorectal cancer, gastroesophageal cancer, head and neck cancer +3 | Fate Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT05378464 | May 2022 → Aug 2026 | HER2 positive breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Suspended | No outcome recorded |
| Phase 1 | NCT05275010 | May 2022 → May 2023 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT05385705 | May 2022 → Jul 2024 | breast neoplasm | Vall d'Hebron Institute of Oncology | Terminated | No outcome recorded |
| Phase 1 | NCT05143970 | Jan 2022 → Mar 2027 expected | breast cancer, endometrial cancer, esophageal cancer, gastric cancer +4 | Institut Paoli-Calmettes | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05069935 | Oct 2021 → Aug 2023 | cancer | Fate Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT03846583 | Jun → Sep 2020 | breast cancer | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT04367090 | May 2020 → Aug 2022 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04188548 | Dec 2019 → Jun 2020 overdue | breast cancer, endometrial cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03716180 | Nov 2018 → Oct 2020 overdue | breast cancer | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03448042 | Jun 2018 → Nov 2027 expected | cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03432741 | Mar 2018 → Aug 2022 | Hodgkins lymphoma, breast adenocarcinoma, mycosis fungoides, nodal marginal zone B-cell lymphoma | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT03319459 | Jan 2018 → May 2020 | HER2 positive breast carcinoma, colorectal cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma +4 | Fate Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03364348 | Oct 2017 → Feb 2021 | HER2 positive breast carcinoma | George W. Sledge Jr. | Completed | No outcome recorded |
| Phase 1 | NCT05765357 | Jul → Oct 2017 | breast cancer, gastric cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02774421 | Jun 2017 → Feb 2025 overdue | posterior fossa ependymoma | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02598427 | May 2017 → Feb 2018 | HER2 positive breast carcinoma | Kimberly Blackwell | Terminated | No outcome recorded |
| Phase 1 | NCT03013218 | Feb 2017 → Feb 2022 | metastatic malignant neoplasm, non-Hodgkin lymphoma | ALX Oncology Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03006172 | Dec 2016 → Dec 2026 expected | breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02738970 | Jun 2016 → May 2018 | female breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02705859 | Apr 2016 → May 2021 | HER2 positive breast carcinoma | Cancer Trials Ireland | Completed | No outcome recorded |
| Phase 1 | NCT02605915 | Dec 2015 → Nov 2019 | HER2 positive breast carcinoma, female breast carcinoma, triple-negative breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02627274 | Dec 2015 → Nov 2022 | breast cancer, head and neck cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02571530 | Aug 2015 → Jun 2021 | metastatic neoplasm | Northwell Health | Terminated | No outcome recorded |
| Phase 1 | NCT02390427 | Apr 2015 → Dec 2022 | breast carcinoma, metastatic neoplasm | Otto Metzger, MD | Completed | No outcome recorded |
| Phase 1 | NCT02152943 | Jul 2014 → Dec 2020 | HER2 positive breast carcinoma, hormone receptor-positive breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02167854 | Jun 2014 → Jul 2021 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02057133 | Mar 2014 → Mar 2021 overdue | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02075073 | Feb → Apr 2014 | — | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02025192 | Dec 2013 → Oct 2017 | HER2 positive breast carcinoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01969643 | Oct 2013 → Feb 2023 | HER2 positive breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01602406 | Sep 2012 → Aug 2017 | HER2 positive breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01705340 | Sep 2012 → May 2013 | HER2 positive breast carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma +1 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT01649271 | Jul 2012 → Jun 2016 | breast cancer, gastric neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01471847 | Feb → Jun 2012 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01434303 | Jan 2012 → Feb 2016 | HER2 positive breast carcinoma, invasive breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01454804 | Oct 2011 → Mar 2015 | high grade malignant neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01432886 | Oct 2011 → Aug 2013 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01300962 | Aug 2011 → Feb 2017 | breast cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01351350 | Feb 2011 → Sep 2017 | hematopoietic and lymphoid cell neoplasm, high grade malignant neoplasm | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01285466 | Jan 2011 → Oct 2014 | cancer of unknown primary site | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01097460 | Apr 2010 → Jul 2013 | breast neoplasm | Merrimack Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00960960 | Aug 2009 → Dec 2015 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00928330 | Jul 2009 → Jan 2014 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00927589 | Jul 2009 → Feb 2013 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00811993 | Feb 2009 → Dec 2012 | neoplasm | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT00800436 | Nov 2008 → Oct 2009 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00543504 | Oct 2007 → Apr 2020 | cancer of unknown primary site | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00426556 | Jul 2007 → Mar 2014 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00470847 | Apr 2007 → Dec 2009 | breast cancer, metastatic malignant neoplasm in the brain | Nancy Lin, MD | Completed | No outcome recorded |
| Phase 1 | NCT00367250 | Jul 2006 → Jun 2011 | breast cancer | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 1 | NCT00803556 | Jan 2006 → Aug 2009 | breast cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00251433 | Sep 2005 → Jun 2010 | breast neoplasm | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT00199212 | Oct 2003 → Dec 2007 | breast carcinoma | Jules Bordet Institute | Completed | No outcome recorded |
| Phase 1 | NCT00068757 | Aug 2003 → Nov 2007 | breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 1 | NCT00039455 | Apr 2002 → Dec 2004 | HER2 positive breast carcinoma, male breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00028535 | Nov 2001 → Feb 2009 | endometrial carcinoma, gastric cancer, male breast carcinoma, malignant epithelial tumor of ovary +2 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00005842 | Jun 2000 → Feb 2004 | cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00014430 | Nov 1999 → Sep 2002 | breast cancer | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00004074 | Aug 1999 → Feb 2009 | PPoma, adenoid cystic carcinoma, adrenal cortex carcinoma, anal squamous cell carcinoma +45 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00009997 | Mar 1999 → Jan 2004 | breast cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT00002994 | Jul 1997 → Mar 2000 | cancer of unknown primary site | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 1/265 trials | ||||||
| Phase 1/2 | NCT06027983 | Nov → Dec 2026 expected | HER2 positive breast carcinoma | National University Hospital, Singapore | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07136428 | Jul 2026 → Nov 2030 expected | HER2 positive breast carcinoma | Duke University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07612215 | May 2026 → May 2029 expected | triple-positive breast carcinoma | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07140393 | Oct 2025 → Oct 2027 expected | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06686394 | Feb 2025 → Apr 2030 expected | breast cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06572319 | Sep 2024 → Aug 2026 overdue | gastroesophageal junction adenocarcinoma | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06650332 | Jul 2024 → Aug 2026 overdue | gastroesophageal cancer | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05785741 | Aug 2023 → Dec 2027 expected | neoplasm | DualityBio Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05749900 | May 2023 → Feb 2026 overdue | — | Yonsei University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05640830 | Jan 2023 → Dec 2025 overdue | carcinoma | Kangbuk Samsung Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05574881 | Sep 2022 → Jan 2025 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05319873 | Apr 2022 → Apr 2027 expected | HER2 positive breast carcinoma, invasive breast carcinoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05091528 | Feb → Jul 2022 | HER2 positive breast carcinoma, non-small cell lung carcinoma | Silverback Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT05081609 | Jan 2022 → Aug 2027 expected | HER2 positive breast carcinoma, cervical carcinoma, melanoma, metastatic neoplasm +2 | Ascendis Pharma A/S | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04464967 | Mar 2021 → Aug 2022 | HER2 positive breast carcinoma, cervical cancer, colorectal cancer, endometrial cancer +9 | NKGen Biotech, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04285671 | Jan 2021 → Dec 2026 expected | non-small cell lung carcinoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04588545 | Dec 2020 → Apr 2027 expected | HER2 positive breast carcinoma, malignant tumor of meninges | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04215003 | Jan 2020 → Dec 2024 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04152057 | Nov 2019 → Apr 2020 | HER2 positive breast carcinoma | West China Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04092673 | Oct 2019 → Dec 2024 | cancer | Effector Therapeutics | Unknown | No outcome recorded |
| Phase 1/2 | NCT03994107 | Oct 2019 → Jan 2021 | breast cancer | Peking Union Medical College | Unknown | No outcome recorded |
| Phase 1/2 | NCT03368729 | Sep 2019 → Nov 2027 expected | HER2 positive breast carcinoma | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03913234 | Jun 2019 → Oct 2023 | HER2 positive breast carcinoma | Yonsei University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03881878 | May 2019 → Oct 2022 | HER2 positive breast carcinoma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT03101748 | Feb 2018 → May 2025 | inflammatory breast carcinoma, metastatic carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04888663 | Feb 2018 → Sep 2021 | — | Yonsei University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03304080 | Dec 2017 → Jul 2026 overdue | breast neoplasm | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03379428 | Nov 2017 → Jan 2025 overdue | breast cancer | US Oncology Research | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02805829 | Jan 2017 → Jan 2020 | gastric cancer | Xuzhou Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02843126 | Jul 2016 → Jul 2017 | breast carcinoma | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT02657343 | Mar 2016 → Aug 2020 | breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02393248 | Feb 2015 → Dec 2021 | breast cancer, cholangiocarcinoma, endometrial cancer, gastric cancer +4 | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02318901 | Oct 2014 → Aug 2018 | breast cancer, cancer of unknown primary site, colorectal cancer, esophageal cancer +1 | Western Regional Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02139358 | Sep 2014 → Apr 2018 | breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02345772 | Jul 2014 → Nov 2015 | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | Western Regional Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02066532 | Jun 2014 → Oct 2020 | HER2 positive breast carcinoma | Dawn L. Hershman | Completed | No outcome recorded |
| Phase 1/2 | NCT02336984 | Jun 2014 → Apr 2016 | breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02154529 | May 2014 → Sep 2015 | HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain | Kadmon Corporation, LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT02120911 | Jan 2014 → Feb 2017 | esophageal cancer | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 1/2 | NCT02030561 | Jan 2014 → Aug 2017 | breast cancer, gastric cancer | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 1/2 | NCT01388647 | Aug 2011 → Jun 2014 | HER2 positive breast carcinoma | Vector Oncology | Terminated | No outcome recorded |
| Phase 1/2 | NCT01306942 | Jul 2011 → Dec 2013 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 1/2 | NCT01373710 | May 2011 → Apr 2018 | breast cancer, neoplastic meningitis | Institut Curie | Completed | No outcome recorded |
| Phase 1/2 | NCT01271920 | Sep 2010 → Oct 2013 | HER2 positive breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00788333 | Jul 2009 → Nov 2011 | breast cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT00923299 | Dec 2008 → Apr 2010 | malignant pancreatic neoplasm | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | No outcome recorded |
| Phase 1/2 | NCT00726180 | Jul 2008 → Jun 2010 | breast cancer | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT00450892 | Feb 2007 → Jul 2013 | breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 1/2 | NCT00258349 | Aug 2006 → Aug 2010 | male breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00317720 | Apr 2006 → Feb 2013 | breast cancer, metastatic neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00331552 | Feb 2006 → Feb 2011 | HER2 positive breast carcinoma, male breast carcinoma | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT00238420 | Jul 2005 → Feb 2014 | urinary bladder carcinoma, urothelial carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00216047 | Jan 2005 → Aug 2006 | breast cancer | Hoosier Cancer Research Network | Terminated | No outcome recorded |
| Phase 1/2 | NCT00337649 | May 2004 → Jul 2007 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT00129896 | Jan 2004 → Dec 2008 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00086957 | Jan 2004 → Aug 2015 | breast cancer | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00095706 | Jun 2003 → Apr 2007 | breast cancer | Translational Oncology Research International | Completed | No outcome recorded |
| Phase 1/2 | NCT02297230 | Jun 2002 → Dec 2014 | breast cancer | NYU Langone Health | Terminated | No outcome recorded |
| Phase 1/2 | NCT00031278 | Oct 2001 → Jun 2003 | breast carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1/2 | NCT00033514 | Aug 2001 → Dec 2011 | breast cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02015676 | Jul 2001 → Sep 2009 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT00006123 | Jul 2000 | female breast carcinoma | Beth Israel Deaconess Medical Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00006825 | Jul 2000 → Jul 2004 | breast cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 1/2 | NCT00004925 | Aug 1999 → Aug 2003 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00006108 | Aug 1999 → Sep 2001 | breast cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2416 trials | ||||||
| Phase 2 | NCT07694986 | Aug 2026 → Aug 2029 expected | breast cancer, neoplastic meningitis | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07565324 | Apr 2026 → Dec 2029 expected | HER2 positive breast carcinoma | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07402473 | Mar 2026 → Dec 2027 expected | HER2 positive breast carcinoma | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT07647263 | Mar 2026 → Jun 2029 expected | HER2 positive breast carcinoma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT07393425 | Feb 2026 → Sep 2027 expected | HER2 positive breast carcinoma | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT07193394 | Jan 2026 → Dec 2028 expected | Her2-receptor negative breast cancer | Institut Curie | Recruiting | No outcome recorded |
| Phase 2 | NCT07290166 | Dec 2025 → Oct 2027 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07340398 | Dec 2025 → Dec 2028 expected | HER2 positive breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07299890 | Dec 2025 → Nov 2027 expected | breast cancer | Anhui Provincial Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07300215 | Dec 2025 → Nov 2027 expected | breast cancer | The First Affiliated Hospital of Bengbu Medical University | Not yet recruiting | No outcome recorded |
| Show all 416 trials opens the full record — a long page | ||||||
| Phase 2/311 trials | ||||||
| Phase 2/3 | NCT07000253 | Apr 2026 → Jun 2031 expected | carcinoma of esophagus, gastric adenocarcinoma | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07366840 | Jan 2026 → Jan 2028 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07332533 | Dec 2025 → Jun 2032 expected | carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05980481 | Aug 2023 → Jul 2025 overdue | gastric cancer | RemeGen Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05786716 | Mar 2023 → Oct 2029 expected | cancer, colorectal neoplasm, gallbladder neoplasm, hematopoietic and lymphoid cell neoplasm +7 | Cancer Research UK | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05722886 | Mar 2023 → Oct 2029 expected | cancer, hematopoietic and lymphoid cell neoplasm | Cancer Research UK | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05002127 | Jan 2022 → May 2024 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | ALX Oncology Inc. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04499924 | Mar 2021 → Apr 2024 | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT03085368 | Mar 2017 → May 2018 | HER2 positive breast carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02581462 | Jun 2016 → Jul 2020 | gastric cancer, gastroesophageal junction adenocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 2/3 | NCT01413828 | May 2011 → Aug 2016 | breast cancer | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 388 trials | ||||||
| Phase 3 | NCT07683754 | Sep 2026 → Jul 2030 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer | Daiichi Sankyo | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06876714 | Sep 2025 → Mar 2028 expected | HER2 positive breast carcinoma | Alliance for Clinical Trials in Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT06992882 | Jul 2025 → Jun 2028 expected | HER2 positive breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06731478 | Feb 2025 → Jun 2028 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Daiichi Sankyo | Recruiting | No outcome recorded |
| Phase 3 | NCT06490536 | Oct 2024 → Mar 2026 overdue | colorectal cancer | IFOM ETS - The AIRC Institute of Molecular Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT05615818 | Jul 2024 → Jun 2027 expected | biliary tract neoplasm | UNICANCER | Recruiting | No outcome recorded |
| Phase 3 | NCT06278870 | Sep 2023 → Jun 2031 expected | HER2 positive breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT07062263 | Jul 2023 → Jul 2029 expected | HER2 positive breast carcinoma, biliary tract cancer | Tata Memorial Centre | Recruiting | No outcome recorded |
| Phase 3 | NCT05883852 | Jun 2023 → Jul 2031 expected | HER2 positive breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05388500 | Dec 2022 → Dec 2030 expected | HER2 positive breast carcinoma | Institut de cancérologie Strasbourg Europe | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05256225 | Nov 2022 → Oct 2027 expected | carcinosarcoma of the corpus uteri, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial mixed adenocarcinoma +2 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT05253651 | Oct 2022 → Dec 2027 expected | colorectal neoplasm | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT05415215 | Jul 2022 → Nov 2024 | female breast carcinoma, inflammatory breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT05188313 | Mar 2022 → Jul 2027 expected | esophageal adenocarcinoma | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 3 | NCT05113251 | Oct 2021 → Mar 2025 overdue | HER2 positive breast carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04973319 | Aug 2021 → Aug 2027 expected | breast cancer | Shengjing Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05429684 | Jan 2021 → Feb 2024 | HER2 positive breast carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 3 | NCT04547907 | Sep 2020 → Dec 2024 overdue | HER2 positive breast carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT03803553 | Apr 2020 → Dec 2026 expected | metastasis from malignant tumor of colon | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04193059 | Dec 2019 → Jul 2026 overdue | breast cancer | Fudan University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04109391 | Aug 2019 → Dec 2021 | HER2 positive breast carcinoma | Tanvex BioPharma USA, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03811418 | Jan → Apr 2019 | HER2 positive breast carcinoma, female breast carcinoma | iOMEDICO AG | Withdrawn | No outcome recorded |
| Phase 3 | NCT03556358 | Jun 2018 → Nov 2020 | HER2 positive breast carcinoma | Tanvex BioPharma USA, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03264547 | Aug 2017 → Dec 2024 | breast cancer | Japan Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT03425656 | Jul 2016 → Mar 2018 | breast cancer | AryoGen Pharmed Co. | Completed | No outcome recorded |
| Phase 3 | NCT02402712 | May 2015 → Feb 2019 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02125344 | Dec 2014 → Nov 2016 | HER2 positive breast carcinoma, breast mucinous carcinoma, female breast carcinoma, inflammatory breast carcinoma +1 | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT02194166 | Jul 2014 → Jul 2018 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02131064 | Jun 2014 → Dec 2015 | breast neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02144012 | Jun 2014 → Jan 2016 | breast cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT02162667 | Jun 2014 → May 2016 | HER2 positive breast carcinoma | Celltrion | Completed | No outcome recorded |
| Phase 3 | NCT02149524 | Apr 2014 → Mar 2016 | HER2 positive breast carcinoma | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02040935 | Feb 2014 → Sep 2018 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01964391 | Feb 2014 → Dec 2016 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02019277 | Dec 2013 → Nov 2016 | female breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01926886 | Nov 2013 → Sep 2015 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01940497 | Nov 2013 → Apr 2016 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01875367 | Sep 2013 → Nov 2016 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT01810393 | Jun 2013 → Jul 2019 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01785420 | May 2013 → Apr 2025 overdue | HER2 positive breast carcinoma | Dr Rajendra A. Badwe | Recruiting | No outcome recorded |
| Phase 3 | NCT01772472 | Apr 2013 → Jul 2018 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01764022 | Oct 2012 → Mar 2015 | HER2 positive breast carcinoma | Biocad | Completed | No outcome recorded |
| Phase 3 | NCT01572038 | Jun 2012 → Sep 2019 | breast neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01566721 | May 2012 → Mar 2015 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01526369 | Feb 2012 → Nov 2015 | breast cancer | Cancer Trials Ireland | Completed | No outcome recorded |
| Phase 3 | NCT01450696 | Dec 2011 → Feb 2015 | gastric cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT01160211 | May 2011 → Mar 2016 | breast neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01196390 | Feb 2011 → Dec 2019 | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT01275677 | Feb 2011 → Jul 2017 | HER2 positive breast carcinoma, progesterone-receptor positive breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT01120184 | Jul 2010 → Sep 2014 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01104571 | Apr 2010 → Aug 2017 | female breast carcinoma | Institute of Cancer Research, United Kingdom | Unknown | No outcome recorded |
| Phase 3 | NCT00968968 | Jan 2010 → Feb 2014 | cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01104935 | Oct 2009 → Oct 2017 | breast cancer | Comprehensive Support Project for Oncology Research | Completed | No outcome recorded |
| Phase 3 | NCT00950300 | Oct 2009 → Jul 2011 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00770809 | Feb 2009 → Jan 2014 | male breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00769379 | Dec 2008 → Dec 2019 | ductal breast carcinoma in situ | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT01917578 | Aug 2008 → Mar 2014 | breast cancer | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
| Phase 3 | NCT00553358 | Jan 2008 → May 2010 | breast neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00629278 | Dec 2007 → Dec 2010 | breast cancer | University Hospital of Modena | Unknown | No outcome recorded |
| Phase 3 | NCT00637325 | Nov 2007 → May 2009 | breast cancer | Regione Lombardia | Unknown | No outcome recorded |
| Phase 3 | NCT00712140 | Oct 2007 → Oct 2011 | breast cancer | Warwick Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT00567554 | Oct 2007 → Aug 2011 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00513292 | Jul 2007 → Jun 2012 | HER2 positive breast carcinoma, female breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00486668 | Jul 2007 → Jun 2012 | invasive breast carcinoma | NSABP Foundation Inc | Unknown | No outcome recorded |
| Phase 3 | NCT00490139 | May 2007 → Dec 2013 | breast neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00448279 | Apr 2007 → Sep 2010 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00381901 | May 2006 → May 2011 | breast cancer | National Cancer Institute, France | Completed | No outcome recorded |
| Phase 3 | NCT00272987 | Dec 2005 → Jul 2009 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00320385 | Nov 2005 → Jun 2007 | breast cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01041404 | Sep 2005 → Jun 2010 | gastric cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00430001 | May 2005 → Dec 2008 | breast cancer | Danish Breast Cancer Cooperative Group | Unknown | No outcome recorded |
| Phase 3 | NCT00288002 | Jan 2005 → ? | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00103233 | Dec 2004 → Apr 2006 | breast cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00615602 | Oct 2004 → May 2012 | female breast carcinoma | Hellenic Oncology Research Group | Completed | No outcome recorded |
| Phase 3 | NCT00148876 | Sep 2003 → Jan 2011 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00440622 | Apr 2003 → Nov 2008 | breast cancer | Hellenic Oncology Research Group | Terminated | No outcome recorded |
| Phase 3 | NCT01998906 | May 2002 → Jul 2012 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00045032 | Nov 2001 → Mar 2005 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00054587 | Jun 2001 → Jun 2009 | breast cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT00016276 | May 2001 → Mar 2005 | female breast carcinoma, inflammatory breast carcinoma, poisoning | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 3 | NCT00021255 | Apr 2001 → Dec 2014 | breast neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00038402 | Apr 2001 → Nov 2004 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00022672 | Jan 2001 → Oct 2009 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00005970 | May 2000 → Apr 2005 | HER2 positive breast carcinoma, breast adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00004067 | Feb 2000 → Mar 2005 | breast cancer | NSABP Foundation Inc | Completed | No outcome recorded |
| Phase 3 | NCT02721641 | Jun 1999 → Feb 2015 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00003440 | Jul 1998 → Jul 2004 | HER2 positive breast carcinoma, Her2-receptor negative breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00053339 | — | female breast carcinoma | Alliance for Clinical Trials in Oncology | Withdrawn | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT07695259 | May 2026 → Dec 2027 expected | HER2 positive breast carcinoma | Wen-Ming Cao | Recruiting | No outcome recorded |
| Phase 4 | NCT06217185 | Jan 2024 → Dec 2025 overdue | HER2 positive breast carcinoma | Hebei Medical University Fourth Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06031233 | Sep 2023 → Jul 2028 expected | — | Isala | Recruiting | No outcome recorded |
| Phase 4 | NCT04928261 | Dec 2021 → Dec 2025 overdue | breast cancer | Ottawa Hospital Research Institute | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05036005 | Jul 2021 → Apr 2023 | HER2 positive breast carcinoma, female breast carcinoma | Institut fuer Frauengesundheit | Unknown | No outcome recorded |
| Phase 4 | NCT02419742 | Aug 2015 → Jun 2021 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT02380131 | Feb 2013 → Dec 2017 | gastroesophageal adenocarcinoma | Hebei Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01260194 | Jun 2011 → Jan 2015 | gastric cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 4 | NCT01301729 | Mar 2011 → Jul 2014 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00127933 | Aug 2005 → Apr 2009 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00171847 | Mar 2003 → Oct 2008 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase not applicable17 trials | ||||||
| — | NCT07589972 | Apr 2026 → Dec 2027 expected | breast carcinoma by gene expression profile | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07187752 | Sep 2025 → Dec 2026 expected | breast cancer | Shandong Cancer Hospital and Institute | Not yet recruiting | No outcome recorded |
| — | NCT07095023 | Aug 2025 → Dec 2026 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| — | NCT06854523 | Apr 2025 → Dec 2026 expected | acute myocardial infarction | Yun Dai Chen | Not yet recruiting | No outcome recorded |
| — | NCT06035679 | Aug 2023 → Nov 2026 expected | female breast carcinoma | Youzhi Zhu | Recruiting | No outcome recorded |
| — | NCT05656079 | Jul 2021 → Sep 2024 | breast cancer | Shanghai Pudong Hospital | Unknown | No outcome recorded |
| — | NCT06907082 | Dec 2020 → Mar 2024 | breast cancer | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Completed | No outcome recorded |
| — | NCT03947242 | Jun 2019 → Jun 2020 | HER2 positive breast carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| — | NCT03847818 | Mar 2019 → Mar 2020 | HER2 positive breast carcinoma | Shandong University | Unknown | No outcome recorded |
| — | NCT02563925 | Sep 2015 → Jul 2021 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT02102438 | Apr 2014 → Apr 2016 | HER2 positive breast carcinoma | Cancer Institute of the State of São Paulo | Withdrawn | No outcome recorded |
| — | NCT01897441 | Jun 2013 → Oct 2023 | female breast carcinoma | Albert Einstein College of Medicine | Terminated | No outcome recorded |
| — | NCT01295086 | Mar 2011 → Nov 2014 | adenocarcinoma | Odense University Hospital | Completed | No outcome recorded |
| — | NCT01048099 | Jan 2011 → Jul 2014 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| — | NCT00535509 | Jun 2007 → Jun 2013 | breast cancer | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT00896376 | Dec 2005 → Dec 2009 | breast cancer | Centre Antoine Lacassagne | Completed | No outcome recorded |
| — | NCT00496808 | Mar 2005 → Nov 2010 | ductal breast carcinoma in situ | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT04220203 | — | HER2 positive breast carcinoma | Pfizer | Approved for marketing | No outcome recorded |
| — | NCT04395508 | — | HER2 positive breast carcinoma | Genentech, Inc. | Approved for marketing | No outcome recorded |
Also used as a comparator or background therapy in 343 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03387553 Background | Jun 2018 → Aug 2023 | HER2 positive breast carcinoma, female breast carcinoma, invasive breast carcinoma, male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 0 | NCT01875666 Comparator | Aug 2013 → Dec 2016 | breast neoplasm | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 155 trials | ||||||
| Phase 1 | NCT06687928 Comparator | Mar → Aug 2025 | — | Celltrion | Completed | No outcome recorded |
| Phase 1 | NCT06770296 Background | Nov 2024 → Nov 2026 expected | breast cancer | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 1 | NCT06625775 Background | Oct 2024 → Nov 2028 expected | HER2 positive breast carcinoma, colorectal cancer, hormone receptor-positive breast cancer, lung carcinoma | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Recruiting | No outcome recorded |
| Phase 1 | NCT06328738 Background | May 2024 → Jan 2027 expected | HER2 positive breast carcinoma, colorectal cancer | Enliven Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06253871 Background | Mar 2024 → Dec 2027 expected | HER2 positive breast carcinoma, gastroesophageal cancer, metastatic malignant neoplasm in the brain, non-small cell lung carcinoma +1 | Iambic Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT06239467 Background | Feb 2024 → Dec 2026 expected | breast cancer | OnKure, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04670796 Comparator | Mar → Jun 2021 | — | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 1 | NCT04487236 Background | Oct 2020 → Apr 2024 | HER2 positive breast carcinoma | Suzhou Zanrong Pharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT04509596 Background | Sep 2020 → Jul 2022 | breast cancer | Dizal Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04120246 Background | Apr 2020 → Feb 2028 | HER2 positive breast carcinoma, female breast carcinoma | Veana Therapeutics | Suspended | No outcome recorded |
| Phase 1 | NCT04253561 Background | Feb 2020 → Dec 2021 | breast cancer | SOLTI Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 1 | NCT04905667 Comparator | Nov 2019 → Sep 2020 | breast cancer | Genor Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04049409 Comparator | Jun → Nov 2019 | — | Taizhou Mabtech Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05301530 Comparator | May 2019 → Aug 2020 | female breast carcinoma | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Completed | No outcome recorded |
| Phase 1 | NCT03776240 Comparator | Apr → Aug 2019 | — | Prestige Biopharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT03680560 Background | Mar 2019 → Mar 2020 | neoplasm | Cogent Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03767335 Background | Nov 2018 → Feb 2024 | breast cancer | Menarini Group | Completed | No outcome recorded |
| Phase 1 | NCT03013881 Comparator | Mar → Oct 2018 | breast neoplasm | United BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT03135171 Background | Jul 2017 → Mar 2020 | breast cancer | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02649686 Background | May 2016 → Sep 2017 | breast cancer | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 1 | NCT03180242 Comparator | Mar → Aug 2016 | — | EirGenix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03242239 Comparator | Feb → Aug 2016 | — | Alteogen, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02665637 Comparator | Dec 2015 → Apr 2016 | — | Celltrion | Completed | No outcome recorded |
| Phase 1 | NCT02569489 Background | Dec 2015 | breast cancer | HUYABIO International, LLC. | Withdrawn | No outcome recorded |
| Phase 1 | NCT02593708 Background | Nov 2015 → Jan 2017 | cancer | Michelle Melisko | Terminated | No outcome recorded |
| Phase 1 | NCT02581748 Comparator | Sep 2015 → May 2016 | — | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 1 | NCT02060253 Background | Apr 2014 → Jun 2018 | HER2 positive breast carcinoma, male breast carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02015156 Comparator | Jan → Feb 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01971515 Background | Dec 2013 → Aug 2018 | cancer | EMD Serono | Completed | No outcome recorded |
| Phase 1 | NCT02594761 Comparator | Aug 2013 → Feb 2014 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT01921335 Comparator | Aug 2013 → Mar 2018 | HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT01603264 Comparator | May → Dec 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04175171 Comparator | Nov 2011 → Jan 2012 | breast cancer | Genor Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01384253 Background | Jul 2011 → Oct 2015 | breast neoplasm, gastric neoplasm, ovarian neoplasm, pancreatic neoplasm +1 | Orano Med LLC | Completed | No outcome recorded |
| Phase 1 | NCT01423123 Background | May 2011 → Aug 2012 | breast cancer | NSABP Foundation Inc | Completed | No outcome recorded |
| Phase 1 | NCT01344863 Comparator | Apr 2011 → Jan 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01880385 Background | Mar 2011 → Sep 2013 | inflammatory breast carcinoma | Association Tunisienne de lutte Contre le Cancer | Unknown | No outcome recorded |
| Phase 1 | NCT01304797 Background | Mar 2011 → Aug 2016 | breast cancer | Merrimack Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1 | NCT01235897 Background | Mar 2011 → Mar 2013 | cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01304784 Background | Jan 2011 → Apr 2014 | carcinoma | Merrimack Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01265927 Background | Jan 2011 → Aug 2012 | breast neoplasm | Indiana University | Completed | No outcome recorded |
| Phase 1 | NCT00963547 Background | Sep 2009 → Aug 2011 | breast cancer | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00950742 Background | Aug 2009 → Oct 2013 | breast cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00807859 Background | Mar 2009 → Feb 2014 | female breast carcinoma, metastatic malignant neoplasm | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00788931 Background | Dec 2008 → Aug 2010 | HER2 positive breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00790816 Background | Oct 2008 → Aug 2016 | breast neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03014076 Comparator | Jan 2008 → Jan 2016 | breast cancer | Cancer Insight, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00412412 Background | Dec 2007 → Apr 2011 | breast cancer | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT00367471 Comparator | Dec 2006 → Dec 2010 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00372424 Background | Dec 2006 → Sep 2011 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00301730 Background | Oct 2005 → ? | breast cancer, metastatic malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00084513 Background | Aug 2004 → Mar 2007 | — | Fox Chase Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00085020 Background | Mar → Dec 2004 | breast cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00042809 Background | May 2002 → Dec 2007 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00022529 Background | Jul 2001 → Jan 2004 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/233 trials | ||||||
| Phase 1/2 | NCT07040059 Comparator | Mar → Dec 2025 | gastroesophageal junction adenocarcinoma | Aurigene Discovery Technologies Limited | Terminated | No outcome recorded |
| Phase 1/2 | NCT06771622 Background | Mar 2025 → Jan 2028 expected | — | FBD Biologics Limited | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06324357 Background | Jun 2024 → Jan 2029 expected | breast cancer, colorectal cancer, esophageal adenocarcinoma, gastric adenocarcinoma +1 | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07334431 Background | Feb 2024 → Dec 2025 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05256745 Background | Jun 2023 → Dec 2026 expected | breast cancer, subjective cognitive decline | Georgetown University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05555251 Background | Jul 2022 → Feb 2024 | HER2 positive breast carcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | BioInvent International AB | Terminated | No outcome recorded |
| Phase 1/2 | NCT04512261 Background | Jun 2022 → Jun 2024 | HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain | Reva Basho | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05207722 Background | Apr 2022 → Feb 2024 | gastroesophageal junction adenocarcinoma | Celularity Incorporated | Terminated | No outcome recorded |
| Phase 1/2 | NCT04108858 Background | May 2021 → Apr 2022 | HER2 positive breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT04750122 Background | Mar 2021 → Jun 2022 overdue | HER2 positive breast carcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05593094 Background | Sep 2020 → Aug 2027 expected | HER2 positive breast carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03112590 Background | Jun 2017 → Mar 2021 | HER2 positive breast carcinoma, female breast carcinoma, male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02901301 Background | Feb 2017 → Oct 2020 | gastric cancer | Yonsei University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04170595 Comparator | Mar 2014 → Dec 2021 | HER2 positive breast carcinoma | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01922921 Background | Feb 2014 → Oct 2019 | HER2 positive breast carcinoma | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT00397501 Comparator | Oct 2013 | breast carcinoma, central nervous system neoplasm, chemotherapy-induced toxicity, cognitive disorder | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02379585 Comparator | Jan 2013 → Aug 2015 | HER2 positive breast carcinoma | Western Regional Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT01746771 Background | Nov 2012 → Aug 2015 | carcinoma | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT01479179 Background | Nov 2012 → Nov 2015 | breast cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01512199 Background | Nov 2011 → Jan 2015 | breast cancer | Daiichi Sankyo | Terminated | No outcome recorded |
| Phase 1/2 | NCT01386580 Background | Jul 2011 → Dec 2014 | breast cancer, lung cancer, malignant glioma, melanoma +1 | BBB-Therapeutics B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT01254136 Background | Oct 2010 → Sep 2011 | breast cancer | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT01132664 Background | May 2010 → Aug 2014 | HER2 positive breast carcinoma, secondary malignant neoplasm | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/2 | NCT01042925 Background | Feb 2010 → Dec 2012 | breast cancer | Sanofi | Completed | No outcome recorded |
| Phase 1/2 | NCT01084863 Comparator | Feb 2010 → Dec 2011 | breast cancer | Celltrion | Completed | No outcome recorded |
| Phase 1/2 | NCT00954512 Background | Sep 2009 → Jun 2011 | neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT00567879 Background | Apr 2008 → May 2011 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/2 | NCT00574587 Background | Dec 2007 → May 2014 | breast cancer | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT00864175 Background | Jul 2007 → Jun 2011 | breast cancer | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT00398567 Background | Apr 2007 → Jul 2009 | breast cancer | Puma Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00458237 Background | Apr 2007 → Apr 2010 | breast cancer | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00140140 Background | Aug 2005 → Feb 2008 | breast cancer | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT00041470 Background | Mar 2001 → Aug 2008 | breast cancer | University of Washington | Terminated | No outcome recorded |
| Phase 2122 trials | ||||||
| Phase 2 | NCT07679269 Background | Jan 2027 → Jun 2031 expected | PIK3CA-related overgrowth spectrum, breast neoplasm | Novartis Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07610720 Background | Jun 2026 → Nov 2028 expected | HER2 positive breast carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07581795 Background | Jun 2026 → Feb 2029 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07545044 Comparator | May 2026 → May 2027 expected | HER2 positive breast carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07616427 Background | May 2026 → May 2028 expected | HER2 positive breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Show all 122 trials opens the full record — a long page | ||||||
| Phase 2/313 trials | ||||||
| Phase 2/3 | NCT07413939 Background | May 2026 → May 2029 expected | HER2 positive breast carcinoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07294508 Comparator | Feb 2026 → Jan 2028 expected | HER2 positive breast carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07294534 Comparator | Jan 2026 → Sep 2028 expected | HER2 positive breast carcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06504732 Comparator | Aug 2024 → Jul 2028 expected | gastric neoplasm | SUNHO（China）BioPharmaceutical CO., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05426486 Comparator | May 2022 → Dec 2025 overdue | HER2 positive breast carcinoma | Caigang Liu | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05189067 Background | Jan 2022 → Jan 2025 | HER2 positive breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04290793 Comparator | Mar 2020 → Dec 2026 expected | breast cancer | Hebei Medical University Fourth Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04082364 Comparator | Sep 2019 → Jan 2024 | gastric cancer, gastroesophageal junction adenocarcinoma | MacroGenics | Completed | No outcome recorded |
| Phase 2/3 | NCT03691454 Background | Jun 2018 → Jun 2022 | gastric adenocarcinoma | Peking University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02568839 Comparator | Nov 2014 → Feb 2019 overdue | HER2 positive breast carcinoma | Thomas Hatschek | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02213744 Background | Jul 2014 → Dec 2016 | HER2 positive breast carcinoma | Merrimack Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2/3 | NCT01426880 Background | Aug 2011 → May 2013 | HER2 positive breast carcinoma, breast mucinous carcinoma, female breast carcinoma, inflammatory breast carcinoma +1 | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 2/3 | NCT00169104 Comparator | Jul 2002 → Mar 2009 | breast cancer | Dartmouth-Hitchcock Medical Center | Terminated | No outcome recorded |
| Phase 3101 trials | ||||||
| Phase 3 | NCT07578116 Background | Mar 2027 → May 2032 expected | HER2 positive breast carcinoma, female breast carcinoma | SWOG Cancer Research Network | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07508956 Background | Jun 2026 → Mar 2029 expected | gastroesophageal adenocarcinoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07528716 Background | May 2026 → Dec 2027 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT07518173 Comparator | Apr 2026 → Dec 2029 expected | HER2 positive breast carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07441460 Comparator | Mar 2026 → Aug 2034 expected | HER2 positive breast carcinoma | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07377643 Comparator | Feb 2026 → Apr 2028 expected | HER2 positive breast carcinoma | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Recruiting | No outcome recorded |
| Phase 3 | NCT07315750 Background | Jan 2026 → Jun 2029 expected | gastric carcinoma | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07239271 Comparator | Nov 2025 → Dec 2027 expected | HER2 positive breast carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07196774 Comparator | Oct 2025 → Dec 2027 expected | breast carcinoma by gene expression profile | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07213206 Background | Oct 2025 → Sep 2032 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07043725 Comparator | Sep 2025 → Sep 2027 expected | HER2 positive breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07118527 Comparator | Aug 2025 → Oct 2030 expected | gastroesophageal adenocarcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07047365 Comparator | Jul 2025 → Jun 2028 expected | HER2 positive breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07057427 Background | Jun 2025 → Jun 2028 expected | breast cancer | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07003074 Comparator | Jun 2025 → Jul 2029 expected | breast cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06764875 Comparator | Mar 2025 → Apr 2029 expected | gastroesophageal junction adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07615751 Background | Feb 2025 → Dec 2028 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06038539 Comparator | Jan → Dec 2025 | HER2 positive breast carcinoma | Biocon Biologics UK Ltd | Terminated | No outcome recorded |
| Phase 3 | NCT06747338 Comparator | Dec 2024 → Dec 2026 expected | HER2 positive breast carcinoma | Shanghai JMT-Bio Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06532006 Background | Nov 2024 → Jun 2027 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 3 | NCT06435429 Comparator | Aug 2024 → Apr 2028 expected | HER2 positive breast carcinoma | Jazz Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07386938 Background | Aug 2024 → Oct 2025 overdue | breast cancer | R-Pharm | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06135714 Background | Nov 2023 → Nov 2026 expected | breast cancer | Tokyo Medical and Dental University | Recruiting | No outcome recorded |
| Phase 3 | NCT06057610 Comparator | Oct 2023 → Oct 2027 expected | HER2 positive breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05838066 Comparator | Jul 2023 → Jul 2025 overdue | breast carcinoma by gene expression profile | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05901935 Comparator | Jul 2023 → Jan 2026 overdue | HER2 positive breast carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05841381 Background | May 2023 → May 2028 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05760612 Background | Mar 2023 → Feb 2028 expected | HER2 positive breast carcinoma, female breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05720026 Background | Jan 2023 → Aug 2025 | HER2 positive breast carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05871918 Background | Oct 2022 → Dec 2023 | HER2 positive breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05474690 Comparator | May 2022 → Mar 2023 | HER2 positive breast carcinoma | Henan Cancer Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT05132582 Background | Mar 2022 → Sep 2025 overdue | HER2 positive breast carcinoma | Pfizer | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05159193 Comparator | Dec 2021 → Oct 2024 overdue | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05152147 Comparator | Dec 2021 → Jul 2026 overdue | esophageal adenocarcinoma, gastric neoplasm, gastroesophageal adenocarcinoma | Jazz Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05346861 Background | Sep 2021 → Oct 2023 | HER2 positive breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT05063786 Background | Sep 2021 → Jun 2026 overdue | breast cancer | Spanish Breast Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04873362 Background | May 2021 → Aug 2028 expected | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04858529 Comparator | Apr 2021 → Apr 2024 | breast carcinoma by gene expression profile | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04784715 Comparator | Apr 2021 → Jul 2026 overdue | HER2 positive breast carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04629846 Background | Nov 2020 → Aug 2022 | breast cancer | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05985187 Background | Oct 2020 → Jan 2023 | HER2 positive breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04208178 Background | Jul 2020 → Feb 2027 expected | HER2 positive breast carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04337658 Background | Jul 2020 → Apr 2024 | HER2 positive breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT04514419 Background | Jun 2020 → Sep 2024 overdue | breast cancer | BioRay Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05629949 Comparator | Apr 2020 → Dec 2022 | breast cancer | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04024462 Comparator | Feb 2020 → Dec 2021 | HER2 positive breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03989037 Comparator | Jun 2019 → Apr 2023 | HER2 positive breast carcinoma | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
| Phase 3 | NCT03705429 Comparator | May 2019 → May 2022 | breast neoplasm | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 3 | NCT03863223 Background | Apr 2019 → Dec 2022 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03199885 Background | Apr 2019 → Apr 2024 | HER2 positive breast carcinoma, breast adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 3 | NCT03726879 Background | Jan 2019 → Feb 2021 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04385563 Comparator | Nov 2018 → Feb 2021 | HER2 positive breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03433313 Comparator | Oct 2018 → Jan 2022 | breast cancer | EirGenix, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03615326 Background | Oct 2018 → Mar 2024 | gastric neoplasm, gastroesophageal junction adenocarcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03595592 Background | Sep 2018 → Dec 2026 expected | invasive breast carcinoma | Fondazione Michelangelo | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04957212 Background | Aug 2018 → May 2020 | HER2 positive breast carcinoma | Cinnagen | Completed | No outcome recorded |
| Phase 3 | NCT03523585 Comparator | Aug 2018 → Jun 2022 | breast cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT03588091 Background | Jul 2018 → Jan 2024 | HER2 positive breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03493854 Comparator | Jun 2018 → Jul 2019 | female breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT06107790 Comparator | May 2018 → Jan 2022 | HER2 positive breast carcinoma | Zhejiang Hisun Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03013504 Comparator | Feb 2018 → Apr 2019 | HER2 positive breast carcinoma | Prestige Biopharma Limited | Completed | No outcome recorded |
| Phase 3 | NCT05301010 Comparator | Feb 2018 → Feb 2021 | female breast carcinoma | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Completed | No outcome recorded |
| Phase 3 | NCT03262935 Comparator | Dec 2017 → Mar 2021 | breast cancer | Byondis B.V. | Completed | No outcome recorded |
| Phase 3 | NCT02947685 Background | Jun 2017 → Oct 2024 overdue | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | Alliance Foundation Trials, LLC. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03084237 Comparator | Nov 2016 → Nov 2018 | breast cancer | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 3 | NCT02896855 Background | Sep 2016 → Jun 2018 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02586025 Background | Mar 2016 → Oct 2017 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02578368 Background | Feb 2016 → Aug 2024 | gastric cancer | Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 3 | NCT02625441 Comparator | Dec 2015 → Jun 2025 overdue | breast cancer | Helsinki University Central Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02344472 Background | Sep 2015 → Jan 2025 | breast cancer | University of Ulm | Unknown | No outcome recorded |
| Phase 3 | NCT02492711 Comparator | Aug 2015 → Aug 2021 | HER2 positive breast carcinoma, metastatic neoplasm | MacroGenics | Completed | No outcome recorded |
| Phase 3 | NCT02514681 Background | Aug 2015 → Dec 2018 | HER2 positive breast carcinoma | Japan Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT02320435 Background | Feb 2015 → Dec 2026 expected | cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02187744 Comparator | Sep 2014 → Mar 2016 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01989676 Comparator | Feb 2014 → Aug 2016 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02003209 Background | Feb 2014 → Oct 2016 | HER2 positive breast carcinoma, hormone receptor-positive breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT01966471 Comparator | Jan 2014 → Nov 2019 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01996267 Comparator | Dec 2013 → Dec 2018 overdue | HER2 positive breast carcinoma | The Netherlands Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01950182 Background | Sep 2013 → May 2020 | breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT01774786 Background | Jun 2013 → Dec 2016 | gastric cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01901146 Comparator | Apr 2013 → May 2016 | female breast carcinoma | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT02472964 Comparator | Jul 2012 → Mar 2016 | breast cancer | Mylan Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01358877 Background | Nov 2011 → Dec 2016 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01125566 Comparator | Jun 2010 → Jun 2013 | breast cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01084876 Comparator | Jun 2010 → Jul 2012 | breast cancer | Celltrion | Completed | No outcome recorded |
| Phase 3 | NCT01026142 Background | Jan 2010 → May 2015 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01007942 Background | Oct 2009 → Jun 2015 | HER2 positive breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00876395 Background | Sep 2009 → May 2014 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00820222 Comparator | Apr 2009 → Jun 2012 | metastatic malignant neoplasm in the brain | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00667251 Comparator | Oct 2008 → Aug 2012 | female breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00625898 Background | Apr 2008 → Jun 2013 | breast cancer | NSABP Foundation Inc | Terminated | No outcome recorded |
| Phase 3 | NCT00567190 Background | Feb 2008 → May 2011 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00593697 Comparator | Jan 2008 → Nov 2014 | breast cancer | Finnish Breast Cancer Group | Completed | No outcome recorded |
| Phase 3 | NCT01613482 Background | Jan 2008 → Aug 2009 | HER2 positive breast carcinoma, metastatic neoplasm | Centre Oscar Lambret | Terminated | No outcome recorded |
| Phase 3 | NCT00520975 Background | Nov 2007 → Oct 2015 | breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 3 | NCT00639366 Background | Feb 2007 → Feb 2010 | breast cancer | Anglo Celtic Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00391092 Background | Sep 2006 → Aug 2014 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00309556 Comparator | Feb 2005 → Nov 2009 | breast cancer | Austrian Breast & Colorectal Cancer Study Group | Completed | No outcome recorded |
| Phase 3 | NCT00047255 Background | May 2002 → Jan 2006 | breast cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00146549 Background | Aug 2001 → Aug 2007 | breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT00004935 Comparator | Aug 1999 → Nov 2014 | breast cancer | Swiss Cancer Institute | Terminated | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT07093931 Background | Aug 2025 → Aug 2027 expected | breast cancer | Shandong Cancer Hospital and Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05376878 Background | Dec 2022 → Apr 2027 expected | invasive breast carcinoma, metastatic malignant neoplasm in the brain | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05420454 Background | Jul 2022 → Jun 2027 expected | breast cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 4 | NCT05420467 Background | Jul 2022 → Jul 2027 expected | breast cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 4 | NCT02445586 Background | Aug 2015 → Sep 2018 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT01501487 Comparator | Oct 2011 → Feb 2016 | breast cancer | Agendia | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07115095 Background | Jan 2021 → Jan 2023 | HER2 positive breast carcinoma | Nanlin Li | Completed | No outcome recorded |
| — | NCT04281576 Background | Dec 2019 → Jun 2024 | gastric cancer, gastroesophageal cancer | NovoCure Ltd. | Completed | No outcome recorded |
| — | NCT03756064 Background | Aug 2019 → Jul 2020 | breast cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| — | NCT03843749 Background | Jul 2019 | colorectal cancer | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| — | NCT06190600 Background | Oct 2018 → Mar 2020 overdue | female breast carcinoma | The Greater Poland Cancer Centre | Active not recruiting | No outcome recorded |
| — | NCT02457039 Comparator | Oct 2015 → Dec 2018 | breast cancer, chemotherapy-induced neuropathy, cognitive impairment with or without cerebellar ataxia, drug-induced mental disorder | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT02226276 Background | Jan 2015 → Dec 2021 overdue | HER2 positive breast carcinoma, bone neoplasm, malignant soft tissue neoplasm, respiratory tract neoplasm | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| — | NCT01503905 Comparator | Dec 2011 → May 2018 | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT00847366 Background | May 2008 → Dec 2012 | breast cancer, non-small cell lung carcinoma, sarcoma | AEterna Zentaris | Completed | No outcome recorded |
| — | NCT00398437 Background | Sep 2006 → ? | breast cancer, metastatic malignant neoplasm | Jules Bordet Institute | Unknown | No outcome recorded |
| — | NCT00433407 Background | Aug 2005 → Feb 2006 | breast cancer, cancer of unknown primary site, lung cancer, ovarian cancer +2 | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
Press releases naming this drug 66 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-09-18 | Novartis Pharmaceuticals | Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab novartis.com ↗ |
| 2021-12-22 | Novartis Pharmaceuticals | Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA novartis.com ↗ |
| 2021-12-20 | Novartis Pharmaceuticals | Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA novartis.com ↗ |
| 2020-12-23 | Roche Global Development | European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer roche.com ↗ |
| 2020-12-14 | Daiichi Sankyo | Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for HER2 Positive Metastatic Breast Cancer daiichisankyo.com ↗ |
| 2020-11-13 | Roche Global Development | CHMP recommends EU approval of Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer roche.com ↗ |
| 2020-07-07 | Daiichi Sankyo | EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer daiichisankyo.com ↗ |
| 2020-06-29 | Roche Global Development | FDA approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer roche.com ↗ |
| 2020-05-07 | Daiichi Sankyo | Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for Treatment of Patients with HER2 Positive Metastatic Gastric Cancer daiichisankyo.com ↗ |
| 2020-03-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection tevapharm.com ↗ |
| 2020-02-25 | Roche Global Development | FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer roche.com ↗ |
| 2019-12-12 | Roche Global Development | Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer roche.com ↗ |
| 2019-12-12 | Daiichi Sankyo | DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 HER2 Positive Metastatic Breast Cancer Trial daiichisankyo.com ↗ |
| 2019-10-17 | Daiichi Sankyo | [Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2 Positive Metastatic Breast Cancer daiichisankyo.com ↗ |
| 2019-09-13 | Roche Global Development | Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer roche.com ↗ |
| 2019-09-09 | Daiichi Sankyo | Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer daiichisankyo.com ↗ |
| 2019-07-19 | Amgen | Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States amgen.com ↗ |
| 2019-06-13 | Amgen | FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab) amgen.com ↗ |
| 2019-05-08 | Daiichi Sankyo | Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need daiichisankyo.com ↗ |
| 2019-04-30 | Novartis Pharmaceuticals | Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors novartis.com ↗ |
| 2019-03-29 | Daiichi Sankyo | Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Positive Metastatic Breast Cancer Post T-DM1 daiichisankyo.com ↗ |
| 2019-03-29 | Daiichi Sankyo | Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201) daiichisankyo.com ↗ |
| 2019-03-11 | Pfizer | U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1 pfizer.com ↗ |
| 2019-02-28 | Roche Global Development | FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers roche.com ↗ |
| 2019-01-15 | Daiichi Sankyo | Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer daiichisankyo.com ↗ |
| 2018-12-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications tevapharm.com ↗ |
| 2018-12-10 | Daiichi Sankyo | Daiichi Sankyo Presents Updated Phase 1 Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Low Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS) daiichisankyo.com ↗ |
| 2018-12-05 | Roche Global Development | Roche's Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment roche.com ↗ |
| 2018-11-28 | Daiichi Sankyo | Daiichi Sankyo Launches Antitumor Agent Trastuzumab Biosimilar for Intravenous Drip Infusions “Daiichi Sankyo” in Japan daiichisankyo.com ↗ |
| 2018-10-26 | Daiichi Sankyo | Daiichi Sankyo Announces Clinical Research Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate [Fam-] Trastuzumab Deruxtecan (DS-8201) with Avelumab and a DNA Damage Response Inhibitor in Patients with HER2 Expressing and Mutated Solid Tumors daiichisankyo.com ↗ |
| 2018-10-22 | Daiichi Sankyo | Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Expressing Advanced Colorectal Cancer at 2018 European Society for Medical Oncology (ESMO) Congress daiichisankyo.com ↗ |
| 2018-09-26 | Daiichi Sankyo | Daiichi Sankyo Initiates Two Phase 3 Trials of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Positive Metastatic Breast Cancer including Head-to-Head Versus T-DM1 and Post-T-DM1 Study daiichisankyo.com ↗ |
| 2018-09-25 | Daiichi Sankyo | Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer daiichisankyo.com ↗ |
| 2018-07-31 | Pfizer | Pfizer Receives European Approval for Oncology Biosimilar, TRAZIMERA™ (trastuzumab) pfizer.com ↗ |
| 2018-06-01 | Pfizer | Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA™ (trastuzumab) pfizer.com ↗ |
| 2018-04-23 | Pfizer | Pfizer Provides Update on Proposed Trastuzumab Biosimilar pfizer.com ↗ |
| 2018-03-23 | Amgen | Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer amgen.com ↗ |
| 2017-09-09 | Pfizer | Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress pfizer.com ↗ |
| 2017-09-09 | Amgen | Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress amgen.com ↗ |
| 2017-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin® (trastuzumab) tevapharm.com ↗ |
| 2017-06-05 | Roche Global Development | APHINITY study shows Roche’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer roche.com ↗ |
| 2017-03-02 | Roche Global Development | Phase III APHINITY study shows Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy roche.com ↗ |
| 2016-11-30 | Pfizer | Pfizer Announces Positive Top-Line Results from the Pivotal Comparative REFLECTIONS B3271002 Study for PF-05280014, a Potential Biosimilar to Herceptin®1 (trastuzumab) pfizer.com ↗ |
| 2016-07-21 | Amgen | Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer amgen.com ↗ |
| 2013-02-22 | AbbVie | ImmunoGen, Inc. Announces FDA Approval of Kadcyla (Ado-Trastuzumab Emtansine; Also Known as T-DM1) abbvie.com ↗ |
| 2012-11-06 | AbbVie | ImmunoGen, Inc. Announces FDA Has Granted Priority Review Status to the Trastuzumab Emtansine (T-DM1) Marketing Application abbvie.com ↗ |
| 2012-10-01 | AbbVie | ImmunoGen, Inc. Announces Overall Survival Data Reported for Trastuzumab Emtansine (T-DM1) Phase III EMILIA Trial abbvie.com ↗ |
| 2012-08-27 | AbbVie | ImmunoGen, Inc. Announces Trastuzumab Emtansine (T-DM1) Significantly Improved Survival in the EMILIA Phase III Trial abbvie.com ↗ |
| 2012-06-03 | AbbVie | ImmunoGen, Inc. Announces Results from Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial abbvie.com ↗ |
| 2012-06-03 | AbbVie | ImmunoGen, Inc. Announces Development of Trastuzumab Emtansine for Early Stage HER2-Positive Breast Cancer abbvie.com ↗ |
| 2012-03-30 | AbbVie | ImmunoGen, Inc. Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial abbvie.com ↗ |
| 2012-03-30 | AbbVie | ImmunoGen, Inc. Announces Conference Call at 8:00 am ET March 30, 2012 to Discuss Today's Favorable Announcements about Trastuzumab Emtansine (T-DM1) and about IMGN901 abbvie.com ↗ |
| 2010-10-08 | AbbVie | ImmunoGen, Inc. Announces Positive Interim Results in Randomized Clinical Trial Comparing Trastuzumab-DM1 vs. Standard First-Line Therapy for First-Line HER2+ Metastatic Breast Cancer abbvie.com ↗ |
| 2010-06-05 | AbbVie | ImmunoGen, Inc. Announces Presentation of Clinical Data for Trastuzumab-DM1 at ASCO Annual Meeting abbvie.com ↗ |
| 2010-04-15 | AbbVie | ImmunoGen, Inc. Announces Favorable Update Provided by Roche Related to Its Trastuzumab-DM1 Regulatory Plans abbvie.com ↗ |
| 2009-12-12 | AbbVie | ImmunoGen, Inc. Announces Positive Trastuzumab-DM1 Clinical Data Reported at the San Antonio Breast Cancer Symposium abbvie.com ↗ |
| 2009-12-12 | Incyte Corporation | Data from a Phase I/II Study Presented at the 32nd San Antonio Breast Cancer Symposium Suggest that INCB7839 in Combination with Trastuzumab May Improve Clinical Response Rates in HER2 Positive Patients with Advanced Metastatic Disease incyte.com ↗ |
| 2009-05-30 | AbbVie | ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented at ASCO abbvie.com ↗ |
| 2009-05-14 | AbbVie | ImmunoGen, Inc. Announces Trastuzumab-DM1 Presentations at the 2009 American Society for Clinical Oncology Annual Meeting abbvie.com ↗ |
| 2009-03-02 | AbbVie | ImmunoGen, Inc. Earns Milestone Payment with Genentech's Start of Trastuzumab-DM1 (T-DM1) Phase III Clinical Testing; Other T-DM1 Progress Reported abbvie.com ↗ |
| 2008-06-03 | AbbVie | ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Findings with Trastuzumab-DM1 at ASCO abbvie.com ↗ |
| 2007-07-31 | AbbVie | ImmunoGen, Inc. Earns Milestone with Start of Trastuzumab-DM1 Phase II Testing abbvie.com ↗ |
| 2006-12-15 | AbbVie | ImmunoGen, Inc. Announces Presentation of First Clinical Data for Genentech's Trastuzumab-MCC-DM1 abbvie.com ↗ |
| 2006-01-31 | AbbVie | ImmunoGen, Inc. Announces Achievement of Milestone in Collaboration with Genentech; Trastuzumab-DM1 IND Becomes Effective, Triggering $2 Million Payment to ImmunoGen abbvie.com ↗ |
| 2002-06-24 | AbbVie | ImmunoGen, Inc. Provides Update on Relationship with GlaxoSmithKline and Also on the Status of Trastuzumab-DM1 abbvie.com ↗ |
| 2001-11-01 | AbbVie | ImmunoGen's Partner Genentech Presents Favorable Preclinical Results of Trastuzumab-DM1 at AACR-NCI-EORTC Meeting abbvie.com ↗ |
Evidence & citations 35 cited values
Every value below carries the sentence it was read from. 1,037 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trastuzumab | “Patients with measurable/evaluable HER2-positive LR/MBC who had not received trastuzumab or chemotherapy for LR/MBC were stratified by prior adjuvant trastuzumab, prior...” PMID 23569311 ↗ Apr 2013953“Patient must have received continuous anti-HER2 targeted therapy (including Trastuzumab, Trastuzumab/Pertuzumab, Trastuzumab-Deruxtecan, T-DM1) for at least 2 years in any line...” NCT06450314 ↗ “This first-in-human study with SB3 was designed to evaluate the pharmacokinetic (PK) equivalence between SB3 and trastuzumab sourced in the European Union (EU trastuzumab),...” PMID 27368117 ↗ Jun 2016 “In this study, the investigators plan multicenter phase II clinical trial to test the efficacy, safety and immunogenicity of trastuzumab biosimilar, Herzuma® in combination...” NCT03755141 ↗ “In patients with ER-positive and HER2-positive breast cancer, the therapeutic potential of combining trastuzumab, pertuzumab, and pyrotinib-representing a triple-targeted...” NCT07290166 ↗ “IAM1363 monotherapy OR IAM1363 in combination with capecitabine + trastuzumab OR IAM1363 in combination with capecitabine + zanidatamab OR IAM1363 in combination with T-Dxd OR...” NCT06253871 ↗ “Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion...” NCT01269346 ↗ “Patients received neoadjuvant chemotherapy consisting of paclitaxel (80 mg/m2, day 1 and 8 of each 21-day cycle, intravenous), trastuzumab (6 mg/kg on day 1 of each cycle...” PMID 41713473 ↗ Feb 2026 “Patients, for whom concurrent HER2 directed therapy trastuzumab is indicated, as determined by the treating investigator, will be enrolled in a parallel HER2 directed therapy...” NCT02563925 ↗ “Phase I/II Clinical Study of the Combination of Disitamab Vedotin and Trastuzumab in the Treatment of HER2 Positive Gastric/Gastroesophageal Junction Tumors With Previous...” NCT06572319 ↗ “Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer” PMID 42150145 ↗ May 2026 “Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks” NCT01669239 ↗ “capecitabine (1000-1250mg/m2, orally, bid, D1-14, q3w) and trastuzumab (first dose 8mg/kg, q3w; Follow-up maintenance 6 mg/kg, q3w, subcutaneous or intravenous for 1 year)” NCT06992882 ↗ “Trastuzumab plus docetaxel was chosen as the comparator in the control group,as it represents a common first-line treatment option used in HER2+ MBC population in China.” NCT04385563 ↗ “Single dose group: lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes” NCT04170595 ↗ “Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks” NCT06276868 ↗ “Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI” NCT00790816 ↗ “Patients with HER2-neu positive breast cancer, will receive the same chemotherapy in combination with intravenous (iv) Herceptin (trastuzumab).” NCT00127933 ↗ “A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.” PMID 12473581 ↗ Dec 2002 “Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)for 6 cycles, administered per USPI (Unites States Prescribing Information) Label” NCT05256745 ↗ “with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles)” NCT03242551 ↗ “According to the results of the genetic mutation status, HER2-positive patients are administered trastuzumab in combination every cycle.” NCT07655024 ↗ “TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) standard of care neoadjuvant chemotherapy regimen” NCT03387553 ↗ “The primary amino acid sequences of trastuzumab in CT-P6 SC are identical to those of the reference drug (EU-approved Herceptin SC).” NCT06687928 ↗ “Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy.” NCT01413828 ↗ “Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles.” NCT01426880 ↗ “Trastuzumab: initial loading dose 8 mg/kg, maintenance dose 6 mg/kg, intravenous infusion, administered once every 3 weeks.” NCT07589972 ↗ “FOLFOX plus anti-HER2 antibody trastuzumab as a second-line or third-line treatment for HER2-positive biliary tract cancer.” PMID 36328033 ↗ Oct 2022 “Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks” NCT01501487 ↗ “Pyrotinib combined with docetaxel, carboplatin and trastuzumab (TCbHPy) for neoadjuvant therapy of HR+/HER2+ breast cancer” NCT05430347 ↗ “Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year” NCT01917578 ↗ “Drug: Trastuzumab Trastuzumab 8mg/kg \[loading dose\] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.” NCT01472146 ↗ “the neoadjuvant treatment regimen of trastuzumab dual-target combined with exemestane and palbociclib for 4 cycles.” NCT07300215 ↗ “EirGenix' Trastuzumab and Herceptin® (Trastuzumab) Sourced From US and EU Administered to Healthy Male Volunteers” NCT03180242 ↗ “Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle” NCT02411344 ↗ “The patient used Trastuzumab 150mg within 24 hours before or after PCI, and then every two weeks for 12 months” NCT06854523 ↗ “Trastuzumab: 4mg/kg IV load dose (TRO 90) minutes followed by 2 mg/kg TRO 60 minutes every week for 18 weeks” NCT01163929 ↗ “Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w)” NCT06254690 ↗ “Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w)” NCT06770296 ↗ “include Trastuzumab (Herceptin) as part of the neoadjuvant treatment in patients who are Her-2 positive.” NCT00830544 ↗ “sequence of Trastuzumab，pyrotinib and Nab-Paclitaxel in first line followed by SHR-A1811 in second line” NCT06975475 ↗ “for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w.” NCT01625429 ↗ “RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways.” NCT00943410 ↗ “Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks” NCT01396707 ↗ “trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w” NCT05346107 ↗ “combined with subcutaneous (SC) fixed dose combination (FDC) of pertuzumab and trastuzumab” NCT04675827 ↗ “CDK 4/6 inhibitor and endocrine therapy combined with Trastuzumab ( without chemotherapy)” NCT07213206 ↗ “Trastuzumab Biosimilar (Herzuma®) in Patients with HER2 Mutated Advanced Solid Cancers” NCT06083662 ↗ “Prior to surgery: trastuzumab, HS627, and docetaxel for 4 cycles (1 cycle = 21 days).” NCT04514419 ↗ “Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways.” NCT00118053 ↗ “Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways.” NCT00138125 ↗ “HER2-Positive: Trastuzumab combined with chemotherapy, with or without immunotherapy.” NCT07257380 ↗ “Targeted therapy: trastuzumab (HER2-positive) or zolbetuximab (Claudin 18.2-positive)” NCT07000253 ↗ “HER2-Positive: Trastuzumab combined with chemotherapy, with or without immunotherapy.” NCT07508956 ↗ “Trastuzumab was administered at 2 mg/kg weekly after a loading dose of 4 mg/kg.” PMID 20705560 ↗ Aug 2010 “containing 15 mL solution of 1200 mg of pertuzumab and 600 mg of trastuzumab.” NCT06172127 ↗ “nab-paclitaxel + carboplatin + trastuzumab + pertuzumab (PCbHP, control arm)” NCT07528716 ↗ “Trastuzumab (iv) will be administered as weekly use or tri-weekly use.” NCT01432886 ↗ “trastuzumab (8 mg/kg loading dose followed by 6 mg/kg Q3W on Day 1)” NCT06548178 ↗ “Paclitaxel, and Trastuzumab in Patients With Operable Breast Cancer” NCT00518583 ↗ “Herceptin® (US-licensed Trastuzumab and EU-licensed Trastuzumab)” NCT03242239 ↗ “Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)” NCT06135714 ↗ “All participants will received trastuzumab and pertuzumab.” NCT04750122 ↗ “pyrotinib combined with trastuzumab and albumin paclitaxel” NCT05429294 ↗ “HER2-positive patients will also receive trastuzumab.” PMID 40953882 ↗ Sep 2025 “docetaxel, carboplatin, trastuzumab, and pertuzumab” NCT07239271 ↗ “Drug: Cetuximab Drug: Trastuzumab Drug: Gefitinib” NCT03768375 ↗ “Docetaxel +Carboplatin+Trastuzumab+Pertuzumab+” NCT07294534 ↗ “Trastuzumab 6 mg/kg IV over 60 minutes day -14” NCT00617942 ↗ “Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg)” NCT03085368 ↗ “docetaxel/carboplatin/trastuzumab/Pertuzumab” NCT04094896 ↗ “trastuzumab (6 mg/kg, loading dose 8 mg/kg)” NCT01996267 ↗ “Pyrotinib in Combination With Trastuzumab” NCT03843749 ↗ “either avelumab, trastuzumab or cetuximab” NCT05069935 ↗ “Trastuzumab 6mg/kg(initial dose 8mg/kg)” NCT05871918 ↗ “trastuzumab reference product (TRZ)” PMID 29448072 ↗ Feb 2018 “Pertuzumab+ Trastuzumab+Docetaxel” NCT07294508 ↗ “Trastuzumab 40 mg/m2，po bid” NCT06036745 ↗ “* Trastuzumab (600mg, SC)” NCT03881878 ↗ “Biological: Trastuzumab” NCT04034823 ↗ “trastuzumab (Herceptin)” NCT00095706 ↗ “trastuzumab, 8 cycles” NCT01206881 ↗ “Trastuzumab * Dose:” NCT02226757 ↗ “Drug: Trastuzumab” NCT06650332 ↗ “Trastuzumab (T)” NCT03262935 ↗ “Trastuzumab” NCT02142036 ↗ |
| Known as | Aryogen Trastuzumab | “A Phase III, Randomized, Two-armed, Triple Blinded, Parallel, Active Controlled Non-Inferiority Clinical Trial of AryoTrust (AryoGen Trastuzumab) Efficacy and Safety in...” NCT03425656 ↗ |
| Known as | AryoTrust | “Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer” NCT03425656 ↗ |
| Known as | CT-P6 | “Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.” NCT06907082 ↗ |
| Known as | EU-Herceptin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03776240 ↗ |
| Known as | FDC of Pertuzumab and Trastuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03493854 ↗ |
| Known as | H SC | “BACKGROUND: This SafeHer subgroup analysis assessed the safety of fixed-dose subcutaneous trastuzumab (H SC) as an adjuvant therapy in HER2-positive early breast cancer (EBC)...” PMID 30018134 ↗ Jul 2018 |
| Known as | Hanquyou | “Trastuzumab (Hanquyou): on the first day of the 21 day cycle, the initial dose was 8mg/kg” NCT05969184 ↗ |
| Known as | Her | “Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy” NCT00004935 ↗ |
| Known as | Herceptin | “The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer] evaluated...” PMID 23569311 ↗ Apr 2013177“This randomized, open-label, parallel, 2-arm, multicenter study will compare the administration of Herceptin (trastuzumab) with a single-use injection device versus a handheld...” NCT01344863 ↗ “Arm I (control arm, 12-month therapy): Patients continue to receive trastuzumab (Herceptin®) IV until a total of 12 months of therapy is completed in the absence of disease...” NCT00381901 ↗ “A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Trastuzumab (Herceptin) in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent...” NCT00258349 ↗ “Trastuzumab for injection is a biosimilar of Herceptin ® produced by Chia Tai Tianqing Biotechnology Co., LTD, which is a humanized IgG1 monoclonal antibody produced by chinese...” NCT05765357 ↗ “One is called trastuzumab (Herceptin®) and it is commonly given to women with early HER2 positive breast cancer or with advanced HER2 positive breast cancer that has spread to...” NCT01276041 ↗ “A Randomized Phase III Study of Trastuzumab (Herceptin) in Combination With Either Vinorelbine (Navelbine), or Taxane-based Chemotherapy in Patients With HER2 Overexpressing...” NCT00146549 ↗ “The purpose of the study is to investigate the effects (good and bad) that the combination of the drugs letrozole (also called Femara™) and trastuzumab (also called Herceptin®)...” NCT00134680 ↗ “A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive...” NCT00950300 ↗ “The drug, docetaxel, is combined with another drug, trastuzumab (Herceptin), because at this time this combination appears to be promising in metastatic breast cancer research.” NCT00146042 ↗ “Prospective Randomised Clinical Trial Testing the Role of Prophylactic Cranial Radiotherapy in Patients Treated With Trastuzumab (Herceptin®) for Metastatic Breast Cancer” NCT00639366 ↗ “Patients receive trastuzumab (Herceptin\^®) IV over 30-90 minutes on days 1, 8, 15, and 22 and docetaxel IV over 1 hour and carboplatin IV over 30-60 minutes on day 8.” NCT00118053 ↗ “Patients then receive paclitaxel IV over 60 minutes and trastuzumab (Herceptin®) IV over 90 minutes on days 1, 8, and 15 and oral lapatinib ditosylate on days 1-21.” NCT00436566 ↗ “Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes and then trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1.” NCT00003612 ↗ “Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15; paclitaxel IV over 3 hours on day 2; and oral capecitabine on days 3-16.” NCT00006108 ↗ “To evaluate if 3 months of trastuzumab (Herceptin®) administered according to the Finnish protocol (9-weekly administrations) is not inferior to 12 months” NCT00629278 ↗ “Those who are Her2+ will initially also receive TEC but subsequent therapy will include Trastuzumab(Herceptin) whether thet respond wellor not to TEC.” NCT01641406 ↗ “Phase II and Pharmacokinetic Study of CPT-11 and Trastuzumab (RhuMab HER2, Herceptin) in Advanced Colo-Rectal Cancer With p185 HER 2 Overexpression” NCT00003995 ↗ “characterize the pharmacokinetic, safety and immunogenicity of CMAB809 versus Trastuzumab(Herceptin) in healthy male subjects after a single dose.” NCT04049409 ↗ “OBJECTIVES: I. Assess the activity of trastuzumab (Herceptin) in patients with progressive androgen dependent and independent prostate cancer.” NCT00003740 ↗ “i.v. Trastuzumab (Herceptin®) and i.v. Paclitaxel as Treatment for Adult Female Patients With HER2 Overexpressing Metastatic Breast Cancer” NCT00788931 ↗ “Patients with HER-2/neu-positive tumors also receive trastuzumab (Herceptin®) IV over 90 minutes on day 1 of each course of chemotherapy” NCT00288002 ↗ “TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) standard of care neoadjuvant chemotherapy regimen” NCT03387553 ↗ “Patients receive docetaxel IV over 30 minutes weekly for 6 weeks plus trastuzumab (Herceptin) IV over 30-90 minutes weekly for 8 weeks.” NCT00006104 ↗ “Herceptin:Lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes.” NCT04170595 ↗ “Patients receive trastuzumab (Herceptin) IV over 90 minutes on days 1, 8, 15, and 22 plus oral R115777 twice daily for 3 weeks.” NCT00005842 ↗ “Patients receive a loading dose of trastuzumab (Herceptin) IV over 90 minutes followed by paclitaxel IV over 3 hours on day 0.” NCT00005635 ↗ “Patients receive a loading dose of trastuzumab (Herceptin®) IV over 90 minutes on day 1 and over 30 minutes on days 8 and 15.” NCT00068757 ↗ “One is called trastuzumab (Herceptin) and it is commonly given to women with advanced and early HER2 positive breast cancer.” NCT02252887 ↗ “Patients then receive trastuzumab (Herceptin®) IV over 30-90 minutes and paclitaxel IV over 1 hour once a week for 12 weeks.” NCT00533936 ↗ “A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German Sourced) in Healthy Chinese Male Subjects” NCT02581748 ↗ “Patients receive trastuzumab (Herceptin) IV over 30-90 minutes followed by paclitaxel IV over 60 minutes on day 1.” NCT00009997 ↗ “in combination with trastuzumab (Herceptin®) in patient with non-resectable liver metastases from breast cancer.” NCT01387295 ↗ “versus Herceptin® (Trastuzumab-EU) approved in the EU in combination with Taxotere® and Carboplatin (Paraplatin)” NCT02187744 ↗ “Trastuzumab (INN; trade name Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor.” NCT00014430 ↗ “Trastuzumab (Herceptin ®): 6 mg/kg every 3 weeks (8 mg/kg as loading dose at 1st administration), iv, d1.” NCT03185988 ↗ “include Trastuzumab (Herceptin) as part of the neoadjuvant treatment in patients who are Her-2 positive.” NCT00830544 ↗ “Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on day 1 and oral exemestane once daily.” NCT00057993 ↗ “Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1.” NCT00238290 ↗ “Patients also receive trastuzumab (Herceptin®) IV over 30-90 minutes once weekly beginning on day 1.” NCT00036868 ↗ “Patients continue or restart trastuzumab (Herceptin) IV over 30-90 minutes weekly or every 3 weeks.” NCT00006381 ↗ “combination of the proteasome inhibitor bortezomib (PS-341, Velcade) with trastuzumab (Herceptin)” NCT00199212 ↗ “irinotecan hydrochloride and trastuzumab (Herceptin®) after prior first- or second-line therapy” NCT00303992 ↗ “Patients are stratified according to prior treatment with trastuzumab (Herceptin®) (yes vs no)” NCT00107393 ↗ “Arm II: Patients receive trastuzumab (Herceptin) IV over 30-90 minutes weekly for 8 weeks.” NCT00005857 ↗ “Patients then receive docetaxel in week 13 and trastuzumab (Herceptin®) in weeks 13-15.” NCT00379015 ↗ “Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle,6 cycles.” NCT04215003 ↗ “Trastuzumab (Herceptin) is an FDA-approved treatment for HER2 positive breast cancer.” NCT02066532 ↗ “trastuzumab (Herceptin), docetaxel, and vinorelbine with filgrastim (G-CSF) support.” NCT00041067 ↗ “Trastuzumab (Herceptin®) is a recombinant DNA-derived humanized monoclonal antibody” NCT05385705 ↗ “trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer.” NCT03085368 ↗ “Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin®).” NCT00182793 ↗ “a drug called trastuzumab (also known as Herceptin®; Roche, Basel, Switzerland).” PMID 32880572 ↗ Aug 2020 “For patients with Her2 positive, add Herceptin 4mg/kg(6mg/kg first cycle) D1” NCT03691454 ↗ “paclitaxel, Herceptin® (trastuzumab), carboplatin, and pertuzumab (PTC-Ptz)” NCT03820063 ↗ “and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year” NCT02934828 ↗ “trastuzumab (Herceptin®) IV over 30-90 minutes once weekly for 3 weeks” NCT00301730 ↗ “Patients receive trastuzumab (Herceptin) IV over 30-90 minutes weekly.” NCT00005033 ↗ “trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15.” NCT00006825 ↗ “Abraxane (nab-paclitaxel), Herceptin (trastuzumab) and carboplatin” NCT00617942 ↗ “trastuzumab [Herceptin] doses when administered with docetaxel” NCT01120184 ↗ “AC-PH (4+4) \[Adriamycin + Cytoxan + Paclitaxel + Herceptin\]” NCT02457039 ↗ “and HER-2 positive patients were added with Herceptin therapy” NCT04510064 ↗ “* Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine)” NCT03414658 ↗ “subjects will receive a dose of trastuzumab (Herceptin®).” NCT00726180 ↗ “trastuzumab (Herceptin\^®) IV over 30-90 minutes on day 1” NCT00093808 ↗ “Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1.” NCT00796978 ↗ “who failed one prior trastuzumab (Herceptin®) treatment” NCT01125566 ↗ “trastuzumab (Herceptin) IV over 30-90 minutes on day 1.” NCT00003992 ↗ “trastuzumab (Herceptin) IV over 30-90 minutes on day 1” NCT00054470 ↗ “trastuzumab (Herceptin) IV over 60-90 minutes on day 1” NCT00053339 ↗ “Anti-HER-2 Monoclonal Antibody Trastuzumab (Herceptin)” NCT00006228 ↗ “trastuzumab (Herceptin®)-naive vs trastuzumab-failure” NCT00086957 ↗ “anthracyclines and taxotere with or without Herceptin” NCT02679040 ↗ “trastuzumab (Herceptin®) IV over 90 minutes on day 1” NCT00084513 ↗ “trastuzumab (Herceptin®) IV over 30-90 minutes” NCT00820872 ↗ “trastuzumab (Herceptin®) IV over 30-90 minutes” NCT00301899 ↗ “trastuzumab (Herceptin \^®) IV over 90 minutes” NCT00088985 ↗ “trastuzumab (Herceptin) IV over 30-90 minutes” NCT00019812 ↗ “trastuzumab (Herceptin\^®) IV over 90 minutes” NCT00085020 ↗ “trastuzumab (Herceptin®) IV over 90 minutes” NCT00103233 ↗ “Trastuzumab (Herceptin®) IV once weekly” NCT00674414 ↗ “Patients receive trastuzumab (Herceptin” NCT00104949 ↗ “monoclonal antibody HER2 (Herceptin)” NCT00003539 ↗ “Herceptin (Trastuzumab fpr Her2 pos)” NCT01426880 ↗ “EU-sourced Trastuzumab (Herceptin®)” NCT04670796 ↗ “Trastuzumab (also called Herceptin)” NCT01205217 ↗ “Drug: trastuzumab (Herceptin®)” NCT00022672 ↗ “* Trastuzumab (Herceptin®)” NCT03765983 ↗ “trastuzumab (Herceptin®)” NCT00138125 ↗ “trastuzumab (Herceptin®)” NCT01104571 ↗ “traztuzumab (Herceptin®)” NCT02167854 ↗ “trastuzumab (Herceptin®)” NCT00433407 ↗ “Herceptin (trastuzumab)” NCT04109391 ↗ “trastuzumab [Herceptin]” NCT02402712 ↗ “Trastuzumab (Herceptin)” NCT07193394 ↗ “Trastuzumab (Herceptin)” NCT07565324 ↗ “trastuzumab (Herceptin)” NCT00095706 ↗ “Trastuzumab [Herceptin]” NCT01130337 ↗ “trastuzumab [Herceptin]” NCT00964704 ↗ “Herceptin (trastuzumab)” NCT00724360 ↗ “trastuzumab [Herceptin]” NCT01290718 ↗ “trastuzumab [Herceptin]” NCT00717405 ↗ “Trastuzumab (Herceptin)” NCT07527806 ↗ “trastuzumab (Herceptin)” NCT00251433 ↗ “Trastuzumab (Herceptin)” NCT07610720 ↗ “trastuzumab [Herceptin]” NCT00811135 ↗ “trastuzumab (Herceptin)” NCT00004925 ↗ “Herceptin (trastuzumab)” NCT01548677 ↗ “trastuzumab [Herceptin]” NCT00885755 ↗ “trastuzumab [Herceptin]” NCT01260194 ↗ “trastuzumab [Herceptin]” NCT01363986 ↗ “Trastuzumab (Herceptin)” NCT06876714 ↗ “trastuzumab [Herceptin]” NCT00444587 ↗ “Drug: Herceptin” NCT00493649 ↗ |
| Known as | Herceptin (trastuzumab) | “Herceptin® (trastuzumab)” NCT00365365 ↗1“Herceptin (trastuzumab)” NCT00412412 ↗ |
| Known as | Herceptin EU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02594761 ↗ |
| Known as | Herceptin Hylecta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07299955 ↗ |
| Known as | Herceptin US | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02594761 ↗ |
| Known as | Herzuma | “D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle)...” NCT03614364 ↗4“Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.” NCT06907082 ↗ “Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1” NCT04722133 ↗ |
| Known as | NSC-688097 | “Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer” NCT00041067 ↗1“Trastuzumab (Herceptin®) (NSC-688097)” NCT00103233 ↗ |
| Known as | Ontruzant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05036005 ↗ |
| Known as | QL1701 | “QL1701 (Trastuzumab for Injection): First dose 8mg/kg, then 6mg/kg, every 3 weeks, for a total of 6 cycles” NCT07299890 ↗ |
| Known as | QL1701 (A trastuzumab biosimilar produced by Qilu Pharmaceutical Co., Ltd) | “QL1701 (A trastuzumab biosimilar produced by Qilu Pharmaceutical Co., Ltd)” NCT07187752 ↗ |
| Known as | RhuMab HER2 | “Phase II and Pharmacokinetic Study of CPT-11 and Trastuzumab (RhuMab HER2, Herceptin) in Advanced Colo-Rectal Cancer With p185 HER 2 Overexpression” NCT00003995 ↗ |
| Known as | SB3 | “Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.” NCT05530057 ↗ |
| Known as | Tmab | “Trastuzumab (Tmab), pertuzumab (Pmab), and taxane has been a standard first-line treatment for recurrent or metastatic human epidermal growth factor (HER2)-positive breast...” PMID 32381018 ↗ May 2020 |
| Known as | Tras | “Trastuzumab (Tras) was administered as an open-label, commercial product at an initial dose of 8 mg/kilograms (kg) over a 90-minute intravenous infusion, followed by 6 mg/kg...” NCT02393248 ↗ |
| Known as | trastuzumab (Herceptine) | “trastuzumab (Herceptine)” NCT02059876 ↗ |
| Known as | Trastuzumab (T) | “Trastuzumab (T)” NCT03262935 ↗ |
| Known as | Trastuzumab Biosimilar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06686394 ↗ |
| Known as | Trastuzumab SC | “Trastuzumab SC is a subcutaneous form of trastuzumab.” NCT04893109 ↗ |
| Known as | trastuzumab-EU | “This randomised, double-blind study compared PF-05280014 (a trastuzumab biosimilar) with reference trastuzumab (Herceptin®) sourced from the European Union (trastuzumab-EU),...” PMID 30568294 ↗ Dec 2018 |
| Known as | TRZ | “trastuzumab reference product (TRZ)” PMID 29448072 ↗ Feb 2018 |
| Known as | TX05 | “This is a Phase III, double-blind, randomized, multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of TX05 (trastuzumab) with Herceptin® in...” NCT03556358 ↗1“TX05 (trastuzumab)” NCT04109391 ↗ |
| Known as | US-Herceptin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03776240 ↗ |
| Action | Deplete | “Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.” NCT00004163 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.” NCT00003440 ↗ |
| Route | Intravenous | “Given IV” NCT00003440 ↗ |
| Target | ERBB2 | “HER-2/neu, the target of trastuzumab” PMID 14981103 ↗ Feb 2004 |